PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0561-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
D. 8 collection of information unless it contains a unlid 0448 contains and the contains a conta

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO	Complete if Known		
	Application Number		
INFORMATION DISCLOSURE	Filing Date		
	First Named Inventor	Rao, G.C. et al.	
STATEMENT BY APPLICANT	Art Unit		
(Use as many sheets as necessary)	Examiner Name		
Sheet 1 of 2	Attorney Docket Number	IMMC 234.1 (CIP)	

			U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2 (# known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/KAC/	1	US- 5610022	03-11-1997	City of Hope Battifora	<u> </u>
	2	<sup>US-</sup> 5981282	11-09-1999	Streck Laboratories Ryan	-
	3	<sup>US-</sup> 5432089	07-11-1995	Streck Laboratories Ryan e	t al
	4	<sup>US-</sup> 5187099	02-16-1993	Coulter Corporation Healy	et al
	5	<sup>US-</sup> 5342754	08-30-1994	Coulter Corporation Maples	et al
	6	<sup>US-</sup> 5763204	06-09-1998	Coulter Corporation Maples	et al
	7	<sup>US-</sup> 5059518	10-22-1991	Coulter Corporation Kortri	ght et al
	8	<sup>US-</sup> 5968831	10-19-1999	Coulter Corporation Shukl	a et al
	9	<sup>US-</sup> 5529933	06-25-1996	Coulter Corporation Young	et al
	10	<sup>US-</sup> 5888823	03-30-1999	Toa Medical Electron Matsu	moto et al
	11	<sup>US-</sup> 5698271	12-16-1997	Immunivest Liberti et	al
	12	<sup>US-</sup> 5597531	01-28-1997	Immunivest Liberti et	al
	13	<sup>US-</sup> 4795698	01-03-1989	Immunivest Owen et al	
	14	US- 5985153	11-16-1999	Immunivest Dolan et a	L
	15	US- 6551843	04-22-2003	Immunivest Rao et al	
	16	<sup>US-</sup> 6623982	01-11-2001	Immunivest Liberti et	al
	17	<sup>US-</sup> 6365362	04-02-2002	Immunivest Terstappen	et al
Ψ	18	<sup>US-</sup> 09/801471	08-30-2001	Immunivest Terstappen	et al
	1	US-			

	Country Code <sup>3</sup> -Number <sup>4</sup> 'Kind Code <sup>5</sup> ( <i>if known</i> )	MM-DD-YYYY		Or Relevant Figures Appear	
_				S. T. S.	T
B1	EP-91306643.7	12-06-1995	Becton Dickinso		
B2	JP-63086915	10-16-1989	TOA Medical Ele		
ВЗ	WO 98/43067	10-01-1998	Immunivest		
B4	WO 02/077604	10-03-2002	Immunivest		
	B2 B3	B2 JP-63086915 B3 WO 98/43067	B2 JP-63086915 10-16-1989 B3 WO 98/43067 10-01-1998	B2 JP-63086915	B2 JP-63086915

Examiner Signature	/Karen A. Canella, Ph.D./	Date Considered	08/14/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 144	I9/PTO	<u> </u>	Complet if Known		
			Applicati n Number		
INFORMAT	TION DIS	CLOSURE	Filing Dat		
STATEMENT BY APPLICANT			First Named Inventor	Rao, G.C. et al.	
			Art Unit		
(Use as many sheets as necessary)		Examiner Name			
Sheet 2	of	2	Attorney Docket Number	IMMC 234.1 (CIP)	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*			T <sup>2</sup>
/KAC/	C1	L. GOMELLA, G. RAJ & J. MORENO, "Reverse Transcriptase Polymerase," The Journal of Urology, 158:326-337 (1997), American Urological Assoc., U.S.A.	
	C2	C. STEWART & J. STEINKAMP, "Quantitation of Cell Concentration," Cytometry, 2(4):238-243 (1982), Wiley-Liss, Inc., New York, NY, U.S.A.	
	СЗ	M. KEENEY, J.W. GRATAMA, I.H. CHIN-YEE & D.R. SUTHERLAND, "Isotope Controls in the Analysis", Cytometry 34:280-283 (1998), Wiley-Liss, Inc., New York, NY, U.S.A.	
	G. STELZER, G. MARTI, A. HURLEY, P.MCCOY, E.J. LOVETT & A. SCHWARTZ, "U.SCanadian Consensus", Cytometry, 30:214-230 (1997), Wiley-Liss, Inc., New York, NY, U.S.A.		
	C5	A. SCHWARTZ, G.E. MARTI, R. POON, J.W. GRATAMA & E. FERNANDEZ-REPOLLET, "Standardizing Flow Cytometry", Cytometry, 33:106-114 (1998), Wiley-Liss, Inc., New York, NY, U.S.A.	
	C6 M.W. LOWDELL & J. LAWRY, "Quality Control in Clinical", Flow Cytometry, ed. M.G. Macey, Blackwell Scientific Publications, Oxford, U.K. (1994), pp. 45-66.		
	C7	H.M. SHAPIRO, Practical Flow Cytometry, Wiley-Liss., New York, NY, U.S.A. (1995), pp. 302-307.	
	С8	F. HAMER, "The Cyanine Dyes", The Chemistry of Heterocyclic Compounds, Interscience Publishers, New York, NY, U.S.A. (1964), pp. 86-115.	
	С9	L. TERSTAPPEN, "Detection of Infrequent", Hematopoietic Stem Cell Transplantation, ed. Ho, Haaas and Champlin, Marcel Dekker, Inc., New York, NY, U.S.A. (2000), pp. 137-152	
		·	

Examiner	Karon A Canolla Ph D /	Date	08/14/2007
Signature	/Karen A. Canella, Ph.D./	Considered	00/14/2007

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.